Patents by Inventor Yaqian TAN

Yaqian TAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug
    Patent number: 11234968
    Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: February 1, 2022
    Assignee: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei Yan, Haipeng Zhang, Yuan Lin, Suizhen Lin, Jing Cai, Shoufang Gong, Jun Hu, Xiao Xiao, Kai Li, Jiankai Liang, Yaqian Tan, Wenbo Zhu, Wei Yin
  • Use of IAP inhibitor and oncolytic virus in preparation of anti-tumor drug
    Patent number: 10980850
    Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: April 20, 2021
    Assignee: Guangzhou Virotech Phamaceutical Co., Ltd.
    Inventors: Guangmei Yan, Jing Cai, Yuan Lin, Haipeng Zhang, Suizhen Lin, Shoufang Gong, Jun Hu, Xiao Xiao, Kai Li, Jiankai Liang, Yaqian Tan, Wenbo Zhu, Wei Yin
  • USE OF BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTITUMOR DRUG
    Publication number: 20190183948
    Abstract: This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 20, 2019
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
    Inventors: Guangmei YAN, Yaqian TAN, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Jing CAI, Wenbo ZHU, Wei YIN
  • USE OF IAP INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTI-TUMOR DRUG
    Publication number: 20190167737
    Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Jing CAI, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
  • USE OF VCP INHIBITOR AND ONCOLYTIC VIRUS IN THE PREPARATION OF AN ANTI-TUMOR DRUG
    Publication number: 20190167641
    Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Haipeng ZHANG, Yuan LIN, Suizhen LIN, Jing CAI, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN